To compare the analgesic effect of 0.1% ropivacaine and 0.2% ropivacaine for femoral nerve block after knee arthroscopy and its effect on quadriceps muscle strength

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041404

Enrollment

Unknown

Registered

2020-12-25

Start date

2019-06-17

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniscus injury

Interventions

experimental group:0.1% Ropivacaine for femoral nerve block

control group:0.2% Ropivacaine for femoral nerve block

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with asa1-2 grade; 2. Patients aged 20-70 years; 3. Patients who are going to undergo knee arthroscopic surgery.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to local anesthetics, sedative analgesics and NSAIDs; 2. Patients with difficulty in opening mouth and unable to insert LMA; 3. Patients with chronic pain, taking opioids or other analgesics for more than one year; 4. The acute stage of trauma, ligament rupture or knee pain lead to significant limitation of knee joint movement.

Design outcomes

Primary

Measure	Time frame
numeric rating scale;Quadriceps muscle strength;	—

Secondary

Measure	Time frame
Knee mobility;post-operative oral opioid dosage;	—

Countries

China

Contacts

Public ContactTao Zhang

Shanghai Tenth People's Hospital

tzhang0415@yahoo.com+86 18017766415

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026